Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited       IL0006290147

SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Teva considering cutting up to 10,000 jobs: Bloomberg

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/08/2017 | 05:54pm CET
FILE PHOTO: The logo of Teva Pharmaceutical Industries, the world's biggest generic drugmaker and Israel's largest company, is seen in Jerusalem

Teva Pharmaceutical Industries Ltd (>> Teva Pharmaceutical Industries Limited) is considering cutting up to 10,000 jobs as CEO Kare Schultz seeks to reduce $1.5 billion to $2 billion in costs over the next two years, Bloomberg reported, citing people familiar with the matter.

Teva Pharmaceutical Industries Ltd (>> Teva Pharmaceutical Industries Limited) is considering cutting up to 10,000 jobs as CEO Kare Schultz seeks to reduce $1.5 billion to $2 billion in costs over the next two years, Bloomberg reported, citing people familiar with the matter.

U.S.-listed shares <TEVA.N> of the debt-laden Israeli drugmaker jumped as much as 7 percent to $16.09 on Friday.

No final decision has been taken, and the targets may be modified, with a range of 5,000 to 10,000 jobs being discussed, Bloomberg reported. https://bloom.bg/2kdYEBI

"We don't comment on market rumors," Teva spokeswoman Denise Bradley said in an emailed statement.

Israeli financial news website Calcalist had reported two weeks ago that the drugmaker would send termination letters to "tens of percent" of its 10,000 employees in the United States.

Schultz, who took over as CEO of the world's largest maker of generic drugs last month, has ousted the company's three top division heads.

Teva is saddled with nearly $35 billion in debt after its $40.5 billion acquisition of Allergan Plc's (>> Allergan plc) generic drug business last year.

Profits from generics have slumped since that deal closed, and the CEO who engineered the purchase was forced to step down earlier this year.

Teva has about 57,000 employees globally, according to the company's website.

(Reporting by Akankshita Mukhopadhyay in Bengaluru; editing by Sai Sachin Ravikumar and Sriraj Kalluvila)

Stocks treated in this article : Teva Pharmaceutical Industries Limited, Allergan plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
01/17 TEVA PHARMACEUTICAL INDUSTRIES : FDA approves Teva leukemia treatment
01/17 TEVA PHARMACEUTICAL INDUSTRIES : U.S. FDA Approves Tevas Trisenox
01/16 TEVA PHARMACEUTICAL INDUSTRIES : Announces U.S. FDA Approval of TRISENOX Injecti..
01/16 TEVA PHARMACEUTICAL INDUSTRIES : Announces U.S. FDA Approval of TRISENOX (arseni..
01/16 TEVA PHARMACEUTICAL INDUSTRIES : Embattled Teva fined NIS 75m. for bribing forei..
01/15 TEVA PHARMACEUTICAL INDUSTRIES : settles graft case with Israeli authorities
01/15 TEVA PHARMACEUTICAL INDUSTRIES : agrees future of Abic Netanya with workers
01/15 TEVA PHARMACEUTICAL INDUSTRIES : corruption settlement doesn't cover co officers
01/15 TEVA PHARMACEUTICAL INDUSTRIES : Announces U.S. FDA Approval of TRISENOX® (arsen..
01/14 TEVA PHARMACEUTICAL INDUSTRIES : Moody's cuts Teva debt to junk status
More news
News from SeekingAlpha
01/18 Generic firms under pressure on possible hospital drug-making venture
01/18 Hospital groups planning to enter generic drugs business
01/18 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 17, 2018
01/18 CTI BioPharma earns $10M milestone from Teva on U.S. OK of Trisenox
01/18 The Re-Balancing Act
Financials ($)
Sales 2017 22 633 M
EBIT 2017 6 276 M
Net income 2017 -
Debt 2017 34 419 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,43x
EV / Sales 2018 2,35x
Capitalization 20 637 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 23,3 $
Spread / Average Target 14%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED12.45%20 637
JOHNSON & JOHNSON5.11%394 542
NOVARTIS1.02%227 089
PFIZER1.05%218 162
ROCHE HOLDING LTD.-5.33%211 361
MERCK AND COMPANY10.24%169 287